Skip to content

Advertisement

Open Peer Review Reports for: A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
19 Aug 2016 Submitted Original manuscript
30 Aug 2016 Author responded Author comments - Patricia M LoRusso
Resubmission - Version 2
30 Aug 2016 Submitted Manuscript version 2
23 Sep 2016 Reviewed Reviewer Report - Roberto Passera
23 Sep 2016 Reviewed Reviewer Report - Nagio Takigawa
21 Dec 2016 Author responded Author comments - Patricia M LoRusso
Resubmission - Version 3
21 Dec 2016 Submitted Manuscript version 3
12 Jan 2017 Author responded Author comments - Patricia M LoRusso
Resubmission - Version 4
12 Jan 2017 Submitted Manuscript version 4
Publishing
15 Feb 2017 Editorially accepted
6 Mar 2017 Article published 10.1186/s12885-017-3143-6

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement